Novartis Ups Ante In Acromegaly Injectables As Oral Contender Emerges

Novartis gears up to file new injectable pasireotide LAR by the end of 2012 for the niche acromegaly market, ahead of the patent expiration of its blockbuster Sandostatin LAR. But Israeli biotech Chiasma is hoping to deliver an oral option with Octreolin.

Novartis AGis hoping to maintain its hold on the acromegaly market by introducing a new injectable for the niche pituitary condition that has better efficacy than the company’s current market leader, Sandostatin LAR (octreotide). But Israeli biotech Chiasma Inc. is making its way through Phase III with an oral version of octreotide, buoyed by a cash infusion.

Novartis – the dominant player in the space – is set to file for approval of the multi-receptor targeting somatostatin...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D